Ventura, Manuela
Bernards, Nicholas
De Souza, Raquel
Fricke, Inga B.
Hendriks, Bart S.
Fitzgerald, Jonathan B.
Lee, Helen
Klinz, Stephan G.
Zheng, Jinzi http://orcid.org/0000-0002-7650-3910
Funding for this research was provided by:
Mitacs (-, -, -)
Merrimack Pharmaceuticals Inc. (-)
Ipsen Biopharmaceuticals (-)
Article History
First Online: 3 September 2019
Change Date: 4 January 2021
Change Type: Correction
Change Details: A Correction to this paper has been published: <ExternalRef><RefSource>https://doi.org/10.1007/s11307-020-01566-w</RefSource><RefTarget Address="10.1007/s11307-020-01566-w" TargetType="DOI"/></ExternalRef>
Compliance with Ethical Standards
:
: All applicable institutional and/or national guidelines for the care and use of animals were followed. All animal studies were approved by the University Health Network (UHN) Animal Care Committee and adhere to the ethical guidelines of the Canadian Council on Animal Care. Fragments of the patient-derived pancreatic tumors OCIP51 and OCIP19 were obtained from the UHN Tumor Tissue Bank in Toronto, ON, Canada.
: Authors affiliated with Merrimack Pharmaceuticals were employees of Merrimack Pharmaceuticals at the time of study and received salaries and stock options from Merrimack Pharmaceuticals. University Health Network has received research funding as part of a sponsored research agreement from Merrimack Pharmaceuticals with Jinzi Zheng as the lead principal investigator.